SAN DIEGO–(BUSINESS WIRE)–Free app is now available, making Android smartphones more accessible for postpaid and no-contract Sprint customers
Author: Business Wire
pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN® for the Treatment of Chronic Diabetic Macular Edema
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces positive outcome to European Decentralized procedure for approval for ILUVIEN for treatment of chronic diabetic macular edema
OptiMedica Begins U.S. Shipments of the Catalys™ Precision Laser System; First U.S. Patients Treated at Mann Eye Institute, Houston
SANTA CLARA, Calif.–(BUSINESS WIRE)–OptiMedica begins shipping the Catalys Precision Laser System for cataract surgery in the U.S. First U.S. patients have been treated at Mann Eye Institute in Houston.
Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
ROCKVILLE, Md.–(BUSINESS WIRE)–RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is updating stockholders on the status of strategic discussions related to its ophthalmic drug candidate, RGN-259. Since…
pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN® for DME and pSivida’s Product Pipeline
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida to hold conference call Monday to discuss product pipeline and CRL from FDA for ILUVIEN
OPKO Announces Sale of Ophthalmic Instrumentation Business
MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE: OPK) has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, man…
AGTC Receives Grant from the Foundation Fighting Blindness for Pre-Clinical Study of Gene Therapy for Eye Disease
GAINESVILLE, Fla.–(BUSINESS WIRE)–AGTC receives significant grant funding from the Foundation Fighting Blindness to develop treatment for genetic eye disease, XLRS, causing blindness in young boys.
Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 1/2 Clinical Trial for OPA-6566 in Patients with Open-angle Glaucoma or Ocular Hypertension
SEATTLE & TOKYO–(BUSINESS WIRE)–Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 1/2 clinical trial for…
EyeMed Vision Care Expands Member Wellness Focus with Diabetic Eye Care Benefit
MASON, Ohio–(BUSINESS WIRE)–EyeMed Vision Care introduces a new Diabetic Eye Care benefit that provides follow-up care and supplementary diagnostic testing for patients with diabetes, a leading cause of adult blindness. Full Story →
Neurotech’s NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy Associated with Dry AMD as Reported in PNAS
LINCOLN, R.I.–(BUSINESS WIRE)–Neurotech announced that it was reported in PNAS that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy associated with dry AMD in a Phase 2 study. Full Story →
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic m…
Alcon Posts Solid Fourth Quarter Financial Results
HUENENBERG, Switzerland–(BUSINESS WIRE)–Alcon, Inc. (NYSE:ACL) reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales growth in the quarter, while foreign…
Research and Markets: Ophthalmic Devices Market Outlook in Japan to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/885688/ophthalmic_devices) has announced the addition of GlobalData’s new report “Ophthalmic Devices Market Outlook in Japan to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others” to their offering. Ophthalmic Devices Market Outlook in Japan…
Research and Markets: Ophthalmic Devices Market Outlook in the United States (US) to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/e86f8c/ophthalmic_devices) has announced the addition of GlobalData ‘s new report “Ophthalmic Devices Market Outlook in the United States (US) to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others” to their offering. Full Story…
Research and Markets: Ophthalmic Devices Market Outlook in India to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/fb0df2/ophthalmic_devices) has announced the addition of GlobalData’s new report “Ophthalmic Devices Market Outlook in India to 2016 – Vision Care, Cataract and Refractive Surgery Devices and Others” to their offering. Ophthalmic Devices Market Outlook in India…
Company Profile for Acucela Inc.
–(BUSINESS WIRE)–Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwid…
Research and Markets: Cataract Surgery – Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/4f2453/cataract_surgery) has announced the addition of GlobalData’s new report “Cataract Surgery – Global Pipeline Analysis, Opportunity Assessment and Market For…
Alcon and Novartis Agree to Merger Terms
HUENENBERG, Switzerland–(BUSINESS WIRE)–Alcon, Inc. (NYSE: ACL) announced today that its board of directors approved a merger agreement with Novartis AG, whereby Novartis will pay a total merger consideration valued at $168 per share for the Alcon shares it does not…
InSite Vision Names Timothy Ruane Chief Executive Officer
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, has appointed Timothy Ruane as Chief Executive Officer (CEO) and elected Mr. Ruane to its Board of Directors, effective Decem…
Company Profile for Iris Pharma
–(BUSINESS WIRE)–Iris Pharma is an independent Contract Research Organization (CRO), dedicated to preclinical and clinical research in ophthalmology.